Cartesian Therapeutics Earns Regenerative Medicine Advanced Therapy Designation for Myasthenia Gravis
shutterstock.com

Cartesian Therapeutics Earns Regenerative Medicine Advanced Therapy Designation for Myasthenia Gravis

Cartesian Therapeutics, Inc., a biotechnology company, recently announced that the FDA has awarded the Regenerative Medicine Advanced Therapy (RMAT) designation to its lead product, Descartes-08, to treat myasthenia gravis (MG).…

Continue Reading Cartesian Therapeutics Earns Regenerative Medicine Advanced Therapy Designation for Myasthenia Gravis
FDA Clears IND Application for Experimental CAR T-Cell Therapy in Myasthenia Gravis
source: shutterstock.com

FDA Clears IND Application for Experimental CAR T-Cell Therapy in Myasthenia Gravis

The biotechnology company Cabaletta Bio has recently announced that the company investigational new drug (IND) application for its experimental CD19-CAR T-cell therapy CABA-201 has been cleared by the US Food…

Continue Reading FDA Clears IND Application for Experimental CAR T-Cell Therapy in Myasthenia Gravis
Rare Community Profiles: Alira Health and the MGFA Partner to Develop a Myasthenia Gravis Registry
source: shutterstock.com

Rare Community Profiles: Alira Health and the MGFA Partner to Develop a Myasthenia Gravis Registry

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: Alira Health and the MGFA Partner to Develop a Myasthenia Gravis Registry
Rare Disease Patients in Bangladesh Struggle with Diagnosis and Treatment
source: pixabay.com

Rare Disease Patients in Bangladesh Struggle with Diagnosis and Treatment

Mazidul Islam told the Daily Star that he had to watch his 14-year-old son Farid die and could do nothing to save him. Among other things, he regrets the fact…

Continue Reading Rare Disease Patients in Bangladesh Struggle with Diagnosis and Treatment